Article
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS.
International journal of chronic obstructive pulmonary disease - 1 Jan 2024
Muro Shigeo, Seki Munehiro, Hurst John R, Petullo David, Marshall Jonathan, Bowen Karin, Darken Patrick F, Duncan Elizabeth A, Megally Ayman, Patel Mehul
Abstract excerpt
Background: We evaluated the inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus dual LAMA/LABA and ICS/LABA therapies in patients with chronic obstructive pulmonary disease (COPD) and phenotypic features of asthma (bronchodilator reversibility and elevated blood eosinophils), but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.